ArticleInfectious diseases and therapy2026
Omadacycline-Associated Pancreatic Injury: a Spectrum from Mild Interstitial to Recrudescent Pancreatitis with Pharmacovigilance Implications.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOmadacycline is a novel aminomethylcycline antibiotic with an incompletely characterized safety profile, particularly regarding pancreatic toxicity. A single case of omadacycline-induced acute pancreatitis has been reported, yet multiple FDA Adverse Event Reporting System (FAERS) analyses have failed to detect a pancreatitis signal. We aimed to characterize the spectrum of omadacycline-associated pancreatic injury and to explore the pharmacovigilance implications of cases presenting with subtle or atypical imaging features.
methodsWe report three cases from an intensive care unit in which patients developed pancreatic enzyme elevation (> 3 × ULN) temporally associated with omadacycline. Alternative etiologies were systematically excluded. Causality was assessed using the Naranjo scale. A literature search of PubMed and Embase was also performed.
resultsAll three patients exhibited predominant hyperlipasemia with CT-confirmed pancreatic injury spanning a severity spectrum. Case 1 (79F) showed lipase > 34 × ULN, peritoneal signs, and new pancreatic head enlargement with peripancreatic stranding (Naranjo 7); Case 2 (18M) had asymptomatic lipase elevation with diffuse glandular swelling and heterogeneous parenchymal density (Naranjo 5); Case 3 (73F) developed recrudescent focal pancreatitis during continued exposure, with tail involvement and perirenal fascial thickening (Naranjo 4). All improved after discontinuation. Common etiologies were excluded. The previously reported case showed an inverse pattern (imaging-dominant with mild enzyme elevation). Collectively, these four cases support upgrading omadacycline from Badalov Class IV to Class III.
conclusionsOmadacycline can cause a spectrum of pancreatic injury, from mild interstitial pancreatitis to recrudescent disease, with CT findings that may be unobtrusive and easily overlooked. This underrecognition likely contributes to underreporting, which may explain the absence of a FAERS pancreatitis signal. Clinicians should monitor lipase and amylase, maintain a low threshold for CT imaging when enzymes rise, and report suspected cases using specific MedDRA terms.
Indexed as
Identifiers
42734716What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.